• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Refractory metastatic Crohn's disease responsive to ustekinumab dose intensification.

作者信息

Xiao Teresa L, Ezenwa Ekene, Ruiz de Luzuriaga Arlene, Hoffman Mark D

机构信息

Pritzker School of Medicine, University of Chicago, Chicago, Illinois.

Section of Dermatology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.

出版信息

JAAD Case Rep. 2022 Dec 5;32:65-67. doi: 10.1016/j.jdcr.2022.11.028. eCollection 2023 Feb.

DOI:10.1016/j.jdcr.2022.11.028
PMID:36654767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9841365/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b315/9841365/de459cab91c4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b315/9841365/55f08cb44eb9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b315/9841365/de459cab91c4/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b315/9841365/55f08cb44eb9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b315/9841365/de459cab91c4/gr2.jpg

相似文献

1
Refractory metastatic Crohn's disease responsive to ustekinumab dose intensification.对乌司奴单抗剂量强化有反应的难治性转移性克罗恩病
JAAD Case Rep. 2022 Dec 5;32:65-67. doi: 10.1016/j.jdcr.2022.11.028. eCollection 2023 Feb.
2
The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.优特克单抗在曾使用抗肿瘤坏死因子药物的克罗恩病患者中的长期临床疗效
Cureus. 2022 Aug 29;14(8):e28536. doi: 10.7759/cureus.28536. eCollection 2022 Aug.
3
Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.英夫利昔单抗或乌司奴单抗治疗炎症性肠病的炎症性皮肤病变：ECCO CONFER 多中心病例系列。
J Crohns Colitis. 2020 Oct 5;14(10):1488-1493. doi: 10.1093/ecco-jcc/jjaa078.
4
Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease.静脉注射乌司奴单抗强化治疗难治性克罗恩病
J Clin Med. 2024 Jan 24;13(3):669. doi: 10.3390/jcm13030669.
5
Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease.乌司奴单抗治疗克罗恩病的长期疗效与抗肿瘤坏死因子药物相当。
J Gastroenterol Hepatol. 2022 Nov;37(11):2105-2112. doi: 10.1111/jgh.15992. Epub 2022 Sep 16.
6
Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.乌司奴单抗谷浓度影响难治性克罗恩病患者的临床和内镜结局：一项中国真实世界研究。
BMC Gastroenterol. 2021 Oct 18;21(1):380. doi: 10.1186/s12876-021-01946-8.
7
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.在接受乌司奴单抗治疗的克罗恩病患者中的临床疗效、药物可持续性和血清药物水平 - 来自匈牙利的前瞻性、多中心队列研究。
Dig Liver Dis. 2022 Feb;54(2):207-213. doi: 10.1016/j.dld.2021.07.008. Epub 2021 Jul 31.
8
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).优特克单抗治疗克罗恩病：来自芬兰的一项全国性真实队列研究（FINUSTE）。
Scand J Gastroenterol. 2019 Jun;54(6):718-725. doi: 10.1080/00365521.2019.1624817. Epub 2019 Jun 11.
9
Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease.治疗药物监测在术后克罗恩病中对肿瘤坏死因子拮抗剂和优特克单抗的应用价值
Inflamm Bowel Dis. 2022 Dec 1;28(12):1865-1871. doi: 10.1093/ibd/izac030.
10
Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease.乌司奴单抗剂量递增可改善难治性克罗恩病的临床反应。
Therap Adv Gastroenterol. 2020 Oct 13;13:1756284820959245. doi: 10.1177/1756284820959245. eCollection 2020.

引用本文的文献

1
Fistulising skin metastases in Crohn's disease: a case report and review of the literature.克罗恩病的瘘管性皮肤转移：病例报告及文献复习。
J Med Case Rep. 2024 May 19;18(1):252. doi: 10.1186/s13256-024-04569-1.

本文引用的文献

1
Ustekinumab Therapeutic Drug Monitoring-Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial.乌司奴单抗治疗药物监测对临床实践的影响：一项多中心横断面观察性研究。
Dig Dis Sci. 2022 Jul;67(7):3148-3157. doi: 10.1007/s10620-021-07173-1. Epub 2021 Aug 17.
2
Metastatic Crohn's disease: an underestimated entity.转移性克罗恩病：一个被低估的实体。
J Dtsch Dermatol Ges. 2021 Jul;19(7):973-982. doi: 10.1111/ddg.14447. Epub 2021 May 7.
3
Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
评估乌司奴单抗在诱导和维持治疗期间的谷浓度，以了解治疗困难的克罗恩病患者的疾病活动状态。
Medicine (Baltimore). 2021 Mar 19;100(11):e25111. doi: 10.1097/MD.0000000000025111.
4
Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.乌司奴单抗治疗炎症性肠病的矛盾性皮肤反应和皮肤表现。
Dermatol Ther. 2021 May;34(3):e14883. doi: 10.1111/dth.14883. Epub 2021 Mar 1.
5
Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.英夫利昔单抗或乌司奴单抗治疗炎症性肠病的炎症性皮肤病变：ECCO CONFER 多中心病例系列。
J Crohns Colitis. 2020 Oct 5;14(10):1488-1493. doi: 10.1093/ecco-jcc/jjaa078.
6
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.乌司奴单抗治疗克罗恩病患者的药代动力学和暴露-反应关系。
Gastroenterology. 2018 May;154(6):1660-1671. doi: 10.1053/j.gastro.2018.01.043. Epub 2018 Feb 1.
7
Metastatic Crohn's disease: a review and approach to therapy.转移性克罗恩病：综述与治疗方法探讨。
J Am Acad Dermatol. 2014 Oct;71(4):804-13. doi: 10.1016/j.jaad.2014.04.002. Epub 2014 Jun 2.
8
Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.瑞士炎症性肠病队列中肠外表现的频率和危险因素。
Am J Gastroenterol. 2011 Jan;106(1):110-9. doi: 10.1038/ajg.2010.343. Epub 2010 Aug 31.
9
Metastatic Crohn's disease: a review.转移性克罗恩病：综述
J Eur Acad Dermatol Venereol. 2008 Sep;22(9):1033-43. doi: 10.1111/j.1468-3083.2008.02741.x. Epub 2008 Jun 19.
10
Use of rifampin in nonstaphylococcal, nonmycobacterial disease.利福平在非葡萄球菌、非分枝杆菌疾病中的应用。
Antimicrob Agents Chemother. 1993 Jan;37(1):1-7. doi: 10.1128/AAC.37.1.1.